Letter: cohort study examining the association between proton pump inhibitors therapy and risk of hepatocellular carcinoma in Taiwan-authors' reply
Aliment Pharmacol Ther
.
2018 Sep;48(6):690-691.
doi: 10.1111/apt.14935.
Authors
Yu-Hsuan Joni Shao
1
2
3
,
Szu-Yuan Wu
4
5
6
7
Affiliations
1
Graduate Institute of Biomedical Informatics, Taipei Medical University, Taipei, Taiwan.
2
Department of Epidemiology, Rutgers School of Public Health, Piscataway Township, New Jersey.
3
Clinical Big Data Research Center, Taipei Medical University Hospital, Taipei, Taiwan.
4
Department of Radiation Oncology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
5
Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
6
Epidemiology and Bioinformatics Center, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan.
7
Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai, China.
PMID:
30132942
DOI:
10.1111/apt.14935
No abstract available
Publication types
Letter
Comment
MeSH terms
Carcinoma, Hepatocellular*
Cohort Studies
Humans
Liver Neoplasms*
Proton Pump Inhibitors
Taiwan
Substances
Proton Pump Inhibitors